Vimpat

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2017
01220082017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Paroxysmal tonic spasms [PTS] are common in patients with neuromyelitis optica spectrum disorder (NMOSD).1 2 In patients with… (More)
Is this relevant?
2014
2014
In a subgroup of patients, traumatic brain injury (TBI) results in the occurrence of acute epileptic seizures or even status… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Lacosamide (Vimpat) is a newly licensed novel antiepileptic drug. We report a case of refractory convulsive status epilepticus… (More)
Is this relevant?
2009
2009
Lacosamide ((R)-2-acetamido-N-benzyl-3-methoxypropionamide; formerly harkoseride, SPM 927; Vimpat), has been recently approved by… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2009
2009
US FDA approvals in 2008 totalled 21 new molecular entities (NMEs) and 3 biologic licence applications (BLAs) that were evaluated… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
Review
2008
Review
2008
Lacosamide (Vimpat) is an aniepileptic drug with a new, dual mode of action. Lacosamide enhances slow inactivation of voltage… (More)
Is this relevant?
2008
2008
In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy… (More)
  • figure 1
Is this relevant?